[单项选择]
{{B}}TEXT C{{/B}}
Growing concerns over the
safety and efficacy of anti-depressant drugs prescribed to children have caught
the eye of Congress and the New York state attorney general. Now they’re
becoming the catalyst for calls to reform the way clinical trials of all drugs
are reported.
Pressure is already causing some changes within
the pharmaceutical industry. And it has put the US Food and Drug Administration
(FDA), which approves new drugs, in the hot seat. If reforms are carried out,
they could bring an unprecedented level of transparency to drug
research.
The solution now under consideration: a public
database, or registry, of drug trials, where companies would post the results of
those trials.
In congressional testimony Thursday, a spokesman
for the American Medical Association endorsed the registry and said it should
include information on each trial’ s purpose and objective, its design, and the
dates i
A. The pharmaceutical industry.
B. US Food and Drug Administration.
C. The Congress.
D. The drug companies.